SURPASS trial programme: difference between revisions
Diff·revision 9 → 10·23:29, 5 Nov 2024
Difference between revision 9 and revision 10 of SURPASS trial programme. 6 lines changed; the page grew by 1,016 bytes.
| Revision 9 — 03:35, 26 Oct 2024 TriumphThad (talk) give the absolute risk difference alongside the relative one 2,611 bytes ±0 | Revision 10 — 23:29, 5 Nov 2024 TrialsTabitha (talk) state that the trial has reported but is not yet peer-reviewed 3,627 bytes +1,016 | ||
|---|---|---|---|
| 26 | Open-label design in SURPASS-2 is a limitation for subjective endpoints and adverse-event reporting, though less so for glycated haemoglobin, which is a laboratory measurement.{{r|ich_e9}} | 26 | Open-label design in SURPASS-2 is a limitation for subjective endpoints and adverse-event reporting, though less so for glycated haemoglobin, which is a laboratory measurement.{{r|ich_e9}} |
| 27 | 27 | ||
| + | 28 | == The head-to-head comparison == | |
| + | 29 | SURPASS-2 randomised 1,879 participants on metformin to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg, for 40 weeks. Glycated-haemoglobin reduction was 2.01, 2.24 and 2.30 percentage points on tirzepatide against 1.86 on semaglutide; weight reduction was 7.6, 9.3 and 11.2 kg against 5.7 kg.{{r|frias2021}} | |
| + | 30 | ||
| + | 31 | The result is a genuine head-to-head at the doses studied, and the doses studied were the approved diabetes doses of both agents at the time. It is not a comparison of maximal doses, and it is not evidence about the obesity indication, where the relevant comparison is between [[SURMOUNT trial programme|SURMOUNT]] and [[STEP trial programme|STEP]] — which are separate trials in separate populations and therefore not a head-to-head at all.{{r|jastreboff2022}} | |
| + | 32 | ||
| 28 | == References == | 33 | == References == |
| 29 | {{reflist}} | 34 | {{reflist}} |
| 30 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> | 35 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> |
| + | 36 | <ref name="jastreboff2022">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide once weekly for the treatment of obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). PMID 35658024.</ref> | |
| 31 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | 37 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> |
| 32 | 38 |